That this House has considered secondary breast cancer.
It is a pleasure to serve under your chairship, Mr Betts. I declare an interest as a governor of the Royal Berkshire hospital; a family member also holds shares in a medical company.
It is a privilege to speak in today’s debate on incurable secondary breast cancer, a debate that the hon. Member for City of Durham (Mary Kelly Foy) and I have brought to Westminster Hall. I thank the many healthcare professionals, charities and life science organisations that have provided valuable information ahead of the debate. I also thank the patients and the charities Breast Cancer Now, Make 2nds Count and METUP UK, who are represented today in the Public Gallery, for their work and support. I would like to recognise everyone involved in the Moments That Count campaign exhibition last November, particularly the brave testimonies from Claire, Laura, Jo, Lisa and Juliet.
As I have mentioned many times in Parliament, I am a breast cancer survivor. That experience showed me the importance of early diagnosis and effective treatment, not only for survival but for the quality of life. My own diagnosis was delayed: I was initially sent away by the first GP I saw, and I waited several months before being diagnosed. During that time, the cancer spread to my lymph glands, which had to be removed. Eighteen years later, I still experience the consequences, most recently just a few weeks ago.
Fortunately, my treatment was successful. For those living with secondary breast cancer, however, a cure is not an option. Secondary breast cancer occurs when the disease spreads to other parts of the body. Treatments can slow its progression and give people more time, but it cannot be cured. About 11,500 women and 90 men die from breast cancer every year, and most of those deaths are caused by secondary breast cancer. For those living with the disease, every extra month matters, yet too often their voices are not heard, their needs are not recognised and time runs out.
I am grateful to the hon. Member and to my hon. Friend the Member for City of Durham (Mary Kelly Foy) for securing this vital debate. I am pleased that it was rescheduled from earlier in the year and that we have the opportunity to be here today.
In advance of this debate, I heard from many women in Newcastle-under-Lyme who have been impacted by breast cancer. I am here to add my voice to their calls for action, to place on the record my support for the More Time to Live campaign and to pay tribute to Breast Cancer Now for all it does. I am grateful to my two colleagues for giving me the opportunity to do so.
I thank the hon. Member for putting his support on the record. This debate is very important: it gives us the opportunity to highlight the experiences of people living with secondary breast cancer and the action needed to support them.
One of the biggest challenges is the lack of reliable data. It is estimated that about 61,000 people in the UK are living with secondary breast cancer, but we do not know that for certain. The disease remains under-recognised, poorly tracked and inadequately recorded. People living with secondary breast cancer are still not consistently counted. Too often, they are invisible within the health system, making it harder to provide the tailored treatment, services and support that they need.
Some 20 years ago, data collection on metastatic breast cancer was identified as a priority by Breast Cancer Now’s secondary breast cancer taskforce. Progress was made in 2013 when mandatory data collection was introduced, and subsequent strategies have promised further improvements, but we are still flying blind. The first two national audits of metastatic breast cancer were unable to provide a complete picture, because recurrence data remains insufficient, both in quality and in completeness. The audit has demonstrated just how important it is that the issue be addressed: without accurate data, the NHS cannot properly plan services, allocate resources or understand the scale of need. Better data could also help to address continuing gaps in access to clinical nurse specialists for people with metastatic breast cancer.
Most importantly, people living with the disease are left feeling that they do not count, because the system cannot guarantee the support that they need. The reality is simple: if we do not know how many people have the disease, we cannot hope to support them effectively. This challenge is not unique to the UK; it is a global issue, and international collaboration can help us to learn from best practice elsewhere, but we should be leading the way. That is why the Government’s national cancer plan is so important. The plan commits to defining and counting recurrent cancers, starting with metastatic breast cancer in 2026. That commitment must now be delivered in full, and Parliament must hold the Government to account on achieving it. The ongoing work of the national disease registration service with NHS trusts to improve data collection is encouraging, but progress will require national leadership and accountability.
I did mention the hon. Member’s constituency first, but I take your guidance, Mr Betts—my apologies for that.
I recently joined a meeting with the hon. Member and with charities including Breast Cancer Now, Breast Cancer Network Australia and Rethink Breast Cancer. Together those charities are working across the UK, Australia and Canada to improve metastatic breast cancer data and ensure that patients’ voices are heard. The message is clear: if we do not count people, we cannot support them. Collecting and publishing this data is essential, because people with metastatic breast cancer count.
Alongside better data, timely access to new treatments is critical. Secondary breast cancer may be incurable, but advances in medicine have transformed outcomes for many patients, giving them more time with the people they love. However, too many patients still struggle to access life-extending treatments on the NHS. One example is Enhertu, a treatment for people with HER2-low metastatic breast cancer. It has the potential to extend and improve lives, yet it was rejected for routine NHS use in England in 2024 on cost grounds. As a result, many patients have been unable to access the treatment that they need. Meanwhile, Enhertu is already available in 26 European countries, including Scotland. England is falling behind. Recent changes to the National Institute for Health and Care Excellence’s cost-effectiveness threshold provide an important opportunity to revisit that decision. I urge Daiichi Sankyo, AstraZeneca, NICE and NHS England to work together to reach an agreement so that patients can access and benefit from Enhertu.
More broadly, concerns remain about how NICE assesses medicines and about the impact on innovation and access to treatments, particularly following the introduction of the severity modifier in 2022. Even after recent changes, the threshold for approving some medicines for metastatic cancer remains lower than before 2022. NICE has estimated that the revisions may result in only three to five additional medicines being approved each year. It is the patients who pay the price. Life-extending treatments exist, but they are not always available to those who need them most. That cannot be right.
Order. I will call Mary Kelly Foy next, as the co-sponsor of the debate. After her speech, I will give hon. Members an indication of how long they may have to speak, to try to get us to the end of the debate in a reasonable fashion.
It is a pleasure to serve under your chairmanship, Mr Betts. I am grateful to have had the opportunity to work with the hon. Member for Wokingham (Clive Jones) to secure this important debate. I thank the campaigners who work to ensure that people living with secondary breast cancer are seen, heard and supported. I am thrilled that my hon. Friend the Member for West Lancashire (Ashley Dalton), who has spoken so openly about her diagnosis, is here today: I am sure that her remarks will be invaluable.
I speak not only as a Member of Parliament, but as someone who has been through breast cancer. I was fortunate: my cancer was picked up through screening and caught early. I received timely treatment and am now cancer-free, but I am forever grateful to the teams at the QE hospital in Gateshead, the Maggie’s centre and Future Dreams for their support. Whenever I can, I encourage people to attend screening appointments and to check themselves. In fact, on 14 July I will be hosting an event alongside leading breast cancer advocates and sporting ambassadors, focusing on raising awareness of the importance of women prioritising their breast health. I would love the Minister to join us.
I know that my personal experience was not that of someone living with secondary breast cancer. For people whose cancer has spread and can be treated but not cured, time is everything. In 2026, it is unacceptable that we do not know with confidence how many people are living with secondary breast cancer. We know that around 60,000 people in the UK are living with it, but that remains just an estimate. More than a decade after data collection was made mandatory, it is still not being consistently or accurately recorded across the country, and if people are not properly counted, their needs are too easily overlooked. The NHS cannot plan the right number of specialist nurses, oncology appointments, palliative care services, mental health support services or clinical trials if the true scale of need is not known.
Order. We have four Members who want to come in, so I will issue a guideline of nine minutes each for speeches, if Members could stick to that, please.
It is a pleasure to serve under your chairmanship, Mr Betts. I want to focus on something that sits at the heart of improving outcomes for people living with secondary breast cancer: data, research and recognition. That especially applies to people suffering from lobular breast cancer.
Last year, my office asked the Government whether the new national audit of metastatic breast cancer would provide a breakdown by breast cancer subtype and hormone receptor status. The response from the Department of Health and Social Care was striking. The Government have effectively admitted that the data is simply not there in any complete or meaningful form. There is still no clear national picture of how many people are living with different forms of secondary breast cancer, what treatments they receive or the outcomes they face. That matters because, if we cannot accurately count metastatic breast cancer patients, we cannot properly plan services, understand needs, target research funding or develop treatments. We cannot fix what we do not measure.
That is especially true for lobular breast cancer. Invasive lobular carcinoma is the second most common form of breast cancer. Twenty-two people are diagnosed with it every day in the UK, yet it remains chronically under-researched and poorly understood. Unlike ductal breast cancer, lobular cancer often does not form a distinct lump. It grows in thin, single-file patterns, making it much harder to detect on standard mammograms and often leading to delayed diagnosis.
Secondary lobular breast cancer also presents further challenges because it tends to be found in untypical places, such as the liver, lungs, brain, bladder and even the eyes, whereas other types of breast cancer spread mostly to the bones. Despite those key biological differences, there is still no specific treatment pathway designed for lobular breast cancer patients. That is extraordinary, considering how many women are affected.
As ever, it is an honour to serve under your chairmanship, Mr Betts.
I first acknowledge the campaigners from Make 2nds Count, METUP UK and Breast Cancer Now and the fellow MBC patients who are joining us in the Public Gallery. If you will indulge me, Mr Betts, I would like to take this opportunity to say a special thank you to my team at the Clatterbridge in Liverpool for the support they have given me through my treatment and diagnosis.
I am delighted to be able to speak in this debate on secondary breast cancer. Secondary, metastatic, advanced, stage 4, disseminated, which a new one for me, distant metastatic spread—lots of words that all mean the same thing: incurable breast cancer. For completeness, there is a relatively new term: oligometastatic, which means very small or very few metastases. There is a school of thought that suggests that that may be curable, but the jury is still out on that, so we will stick with the terms that we have. But there are some other words that describe secondary breast cancer: devastating, terrifying, overwhelming, horrifying, desperate, anger, resentment and fear—all of which I have certainly felt.
This debate calls it secondary breast cancer. It is really important that we get it right, because I have met many people who think that secondary breast cancer means having breast cancer for the second time. It does not. Let me be really clear about that. As we have heard, secondary breast cancer is breast cancer that has spread outside the breast tissue and is now incurable. It can be diagnosed after a primary diagnosis—primary breast cancer is potentially curable—or the first time that a person is diagnosed with breast cancer. That is called a de novo diagnosis. That is what secondary breast cancer is and, as we have heard, I have it, along with many, many other people.
I want to take the opportunity to talk about some of the myths around breast cancer. Colleagues have spoken really well about some of the issues and concerns, and the politics and policies involved, but I want to talk about the reality and some of the myths about secondary breast cancer. The big myth for many people is that it is curable. A number of people have, very well-meaningly, said to me, “How long will you be on treatment?” I will be on treatment until I die. “I hope you make a full recovery.” I am not going to be making a recovery. My favourite—I know people mean well—is: “If anyone can beat this, you can.” I know people mean well when they say that, but the truth is that I cannot beat it. I will always be in treatment, and I will not recover. It is absolutely terrifying, but we have to be honest about this. If we are not honest and do not grasp the nettle about this disease, we cannot truly tackle it.
It is a pleasure to serve under your chairship, Mr Betts. I thank the hon. Members for Wokingham (Clive Jones) and for City of Durham (Mary Kelly Foy) for calling attention to this disease, and I thank the hon. Member for West Lancashire (Ashley Dalton) for her spirit and courage; it always touches me and makes me quite proud of her. I wanted to put that on the record.
The hon. Member for Fermanagh and South Tyrone (Pat Cullen), some local ladies, Tristan Loraine and I had a meeting with Health Minister Mike Nesbitt in Northern Ireland some four or five weeks ago to discuss the issue of lobular cancer. It was an important meeting because those ladies around the table were ladies like the hon. Lady for West Lancashire; they were ladies who had cancer, were living with it and were trying to deal with it. Their personal stories really touched me because almost every one of those ladies had children. One lady had four young children, and I was moved by her contribution and very touched by the life that she was leading with four young children.
Each month in the UK, around 1,000 people die from secondary breast cancer, which equates to one life every 45 minutes. That stat paints a harrowing picture of the devastating impact that secondary breast cancer has on many individuals and their families. Although the cancer is not curable, as it has metastasised, it is treatable and can often be managed. On average, patients can survive two or three years or more after diagnosis. Symptoms can be relieved, and patients’ quality of life can be maintained, with many leading a “normal life”.
In 2024, secondary breast cancer was deemed “moderately severe”, meaning that funding would not be granted in Wales, England and Northern Ireland. My request is that we have access to the licensed Enhertu drug, which is used to slow the cancer’s progression and maintain quality of life for patients. It is incredibly difficult to justify a system in which patients in Scotland and more than 20 other European countries can access this treatment, while eligible patients in England, Wales and Northern Ireland cannot. It just does not make sense. Mental health support should also be invested in across the United Kingdom to ensure that patients and their families receive emotional support to help them cope.
20 of 36 shown
I am delighted that the hon. Member for West Lancashire is here today. Ashley Dalton was the Minister who drove the national cancer plan through Parliament.
The commitments in the national cancer plan to streamline medicine approvals and accelerate clinical trials are welcome. The recent UK-US pharmaceutical agreements, including commitments to strengthen support for the life sciences sector, are likewise welcome, but without meaningful investment in innovative medicines for severe conditions, access will remain limited and patients will continue to miss opportunities for longer and better lives. Support services also remain inadequate.
Clinical nurse specialists play a vital role in guiding patients through complex treatment pathways and providing emotional support, yet many people with secondary breast cancer still do not have access to a clinical nurse specialist. Even among those who do, a quarter have not seen their specialist since diagnosis, and only 65% feel that their specialist has enough time for them. The reason is simple: caseloads are too high. We must recognise the profound emotional impact of secondary breast cancer. More than a quarter of patients say that they did not receive enough mental health support. Many need greater support for their family as well. The NHS long-term plan promised every cancer patient access to a clinical nurse specialist or support worker. That commitment must now be delivered for people with secondary breast cancer who need specialist expertise to navigate this complex disease.
People living with metastatic breast cancer do not have time to wait. They need to be counted. They need access to the support they deserve. They need rapid access to treatments that can give them more precious time with the people they love. I ask the Minister for two clear commitments. First, will she set out a timeline for delivering the national cancer plan’s commitment to define and count recurrent cancers, starting with metastatic breast cancer in 2026, and will she outline any plans to make the data that is currently held by the national disease registration service publicly available? Secondly, what are the Government doing to support metastatic breast cancer patients who may miss out on life-extending medicines because of pricing and access barriers?
I welcome the work of the national disease registration service, with NHS trusts, to improve data returns on metastatic breast cancer, but I am concerned that no data has yet been published. I also welcome the Government’s commitment to the national cancer plan, to define and count recurrent cancers, starting with metastatic breast cancer, and to ensure that patients have named primary contacts, but patients need delivery now, not just commitment. The NHS must routinely capture data on not only diagnosis but treatment and support needs. That is how we can move from counting people in theory to improving the services available to them in practice.
In Durham, trust was shattered when failures were identified in breast services at County Durham and Darlington NHS foundation trust. The concerns went way beyond isolated mistakes, and patients wondered whether the care that they received was truly in line with the standards that they should expect. Patients place their lives in the hands of the system, so they deserve to know that decisions about their care are evidence-based, properly scrutinised and made through strong, multidisciplinary teams. When that trust is broken, it is difficult to rebuild. I pay tribute to those who spoke out, such as my constituent Jackie, who did so on behalf of her sorely missed daughter, Michaela, and Amelia, Cat and Nadeen, who formed the Pink Justice Network. I do also recognise the efforts of the new senior leadership team at the trust, who are working to reform services and repair patient confidence.
On access to treatments, everyone living with secondary breast cancer deserves to have access to new, effective life-extending treatments, but there are serious concerns that the way in which NICE currently assesses some drugs limits access for people living with incurable metastatic breast cancer. Campaigners have warned that since the introduction of the severity modifier, some advance cancer treatments have been disadvantaged compared with the previous system. Breast Cancer Now reports that only a minority of end-of-life treatments assessed under the new approach received the same level of priority as they would have before.
The clearest example is Enhertu, which could give people with HER2-low metastatic breast cancer more time, yet was not recommended for routine NHS use in England in 2024, as a cost-effective pricing agreement could not be reached. Since then, eligible patients have missed out, and people have asked why a life-extending treatment should be available in Scotland but not in England. The Government’s decision to increase the NICE cost-effectiveness threshold for new medicines is welcome, and I hope it will create an opportunity to reach an agreement on Enhertu. I also welcome the fact that discussions between AstraZeneca, Daiichi Sankyo, NHS England and NICE are understood to have begun. More than 50,000 people have signed a petition calling for urgent agreement on Enhertu. They are asking for something very simple: that all parties come together to find a way to give eligible patients more time.
I must also mention the work of our hospices, such as St Cuthbert’s hospice in Durham, which are supported by charities such as Marie Curie, in providing people who are living with secondary breast cancer with the services that they need. Marie Curie reports that one in three people do not receive the care and support they need at the end of life, so I welcome the fact that the Government are developing a palliative care and end-of-life care modern service framework. I hope that the framework will address the lack of support available outside of normal working hours, embed palliative care in neighbourhood health and ensure that the palliative care workforce is fit for the future.
Will the Minister set out how the Government will ensure three things: first, that secondary breast cancer data is collected and published consistently across every trust, with clear accountability for delivery; secondly, that every patient has meaningful access to a specialist named contact with the time and capacity to support them properly; and thirdly, that people living with secondary breast cancer are not left behind when life-extending treatments become available?
Secondary breast cancer is not just a diagnosis. Mothers miss milestones, daughters face uncertain futures, partners become carers and families must live with a clock that they never asked to hear ticking. We do not ask for kind words today, but for action on research, access to treatment, support and giving people more time not just to survive, but to live—because behind every diagnosis is a person who still has dreams, plans and a life worth fighting for.
For too long, secondary and metastatic lobular breast cancer has existed in a blind spot. Historically, cancer registries have focused on primary diagnoses and have often failed to track recurrence or progression properly. Mandatory reporting has improved matters somewhat over the last decade, but huge gaps remain. That is why the work of campaigners and researchers has been so important.
I especially want to recognise and pay tribute to Dr Susan Michaelis, founder of the Lobular Moon Shot Project. She was one of my Horsham constituents, and she sadly died of lobular breast cancer almost a year ago. Susan was relentless in pushing this issue into public view. She understood that, without data, dedicated research and recognition that lobular breast cancer is different, progress would remain unacceptably slow. Her work has already helped encourage NHS England to release the first dedicated statistics on lobular breast cancer, but much more needs to happen.
This is about more than statistics. It is about people living for years with secondary breast cancer while feeling invisible within the system. Better subtype data would help us understand metastatic disease properly. Better research would improve diagnosis and, ultimately, dedicated treatment pathways for lobular breast cancer could help us move closer to what patients want to hear most of all: that their cancer is not just treatable, but curable.
The Lobular Moon Shot Project is looking for just £20 million over five years to fund research into the basic biology of lobular breast cancer. Researchers at the Manchester Breast Centre are ready and willing to take on the mission—they could start tomorrow. The Lobular Moon Shot Project is supported by more than 460 sitting MPs, more than can be found on any other single issue. All it needs now is for the Government to press the button. While we wait for that, women face poorer outcomes and require medications that were actually designed for other types of cancer, which cost upwards of £3,000 per month. Now is the time for the Government to commit to front-loaded funding to save lives, save money for the NHS and, most of all, demonstrate to those women that they matter. I ask the Minister for her support in finding the modest investment required to find answers for this very common but, sadly, much-neglected disease.
There are some other myths about breast cancer. One is that when it spreads, it is a new cancer. If you have breast cancer and then you have cancer in your bones, that is not bone cancer; it is breast cancer in your bones. It looks like breast cancer and the cells are breast cancer; they behave like breast cancer and they will need to be treated like breast cancer. There is also a myth that the treatment for your primary cancer was somehow wrong or had failed if you get metastatic breast cancer. Again, that is absolute nonsense. Breast cancer can still spread, even after successful treatment for a primary cancer, and even with the best treatments in the world. Breast cancer in particular can lie dormant for years and years.
That leads me to the five-year myth. We often count survival after primary diagnosis and treatment at the five-year point. Sometimes, that creates the idea that if you get to five years and it has not come back, you are okay. Sadly, that is not true; it does not mean that it will never come back. Breast cancer in particular can come back up to 20 years, if not longer, after primary diagnosis. My breast cancer came back 10 years after my primary diagnosis. I do not say that to terrify people, but to say that it is absolutely imperative that they are aware of the signs and symptoms of secondary breast cancer in case they ever have them, no matter how long it has been since their primary diagnosis—or indeed, if they have ever had one. I put on record my commendation and thanks to Jo from METUPUK, who developed the infographic on secondary breast cancer symptoms, which has been extremely useful.
We have heard about lobular breast cancer, and there is an idea that secondary breast cancer is one disease. Obviously, it is not: there is ductal, lobular, metaplastic, inflammatory and other sub-groups such as hormone receptive, HER2-positive, HER2-negative and triple negative. The weird thing about cancer is that it is not a disease that infects us. It is not something from outside that we pick up, or that we get. It is us—it is our own cells that change and do this to us, so our cancer, invariably, is as unique as we are. There is also a myth that all treatments will work for everybody, and that if you have one kind of cancer, a certain treatment will work. Unfortunately—sadly—that is not the case, because we are all unique. A treatment that can be extremely effective for one person can have absolutely no impact on somebody else.
There is also the idea that the treatment for metastatic breast cancer is more aggressive than that for primary cancer; actually, it is often the opposite. I cannot be cured, so what is the point of making me so sick that I cannot get out of bed for six months? The point of treatment is to keep the cancer at bay—to hold it back to allow me to continue to do this work and live my life—not necessarily to cure me.
Then there is the myth that metastatic breast cancer means that you are going to die soon. I received some absolutely terrible comments when I went public with my disease. One particularly lovely person on Facebook said, “Oh, there’ll be a by-election soon then,” assuming that I was going to be dead—that was two years ago. It is not necessarily true. Metastatic breast cancer is treatable, but it is not curable. Our treatments are there to hold it at bay and treat pain and other side effects. Sometimes we might even get the holy grail of “no evidence of disease”, which is what everybody hopes for. That does not mean that you are necessarily cancer free, because we know that it lies dormant and we cannot necessarily see it.
We know what secondary breast cancer is, so what are we going to do about it? Some of these points have been raised already, but the national cancer plan, which I, as the Minister at the time, was delighted to lead on and launch earlier this year, is perhaps the first national cancer plan that does not have metastatic disease as a brief mention but has it at its heart. I am really pleased about that, because it has not been forgotten about—it is in the plan.
The No. 1 thing that I wanted to make sure was in the plan was that we count; this has already been touched on. We estimate that 61,000 people have metastatic breast cancer, but really we have not got a clue. We have some good data for de novo—where it is diagnosed initially—but for people like me who are diagnosed 10, 12 or 20 years later, we do not really know. Without that data, we cannot build the services or estimate demand. The fundamental truth is, if I am not counted, I do not count. We must start this. The cancer plan commits to counting metastatic disease properly, starting with breast cancer, so I ask the Minister what progress has been made, and will she set a deadline for trusts to report? It is literally just counting.
On research and lines of treatment, some treatments work and some of them do not. Basically, you try them, and if they work, you stay on them until they stop working or they make you so ill that you cannot carry on, and then you try another one. It is literally a process of trial and error, and you keep going until you run out of options, which means that without access to new drugs and without trials, we will run out of options sooner rather than later, and when we run out of options, we die.
The cancer plan committed to develop world-class cancer care through world-class research, so I ask the Minister what progress has been made, particularly to establish the cancer trials accelerator by 2027. When we do develop those drugs, we need to know that we are getting them. Changes to NICE criteria, namely the severity modifier, have been touched on, so I ask the Minister what developments have been made on them. Will she explore those? Access to drugs and research makes it possible for me and others like me to see our children grow, to meet our grandchildren and to bury our parents, not the other way round. Lives with metastatic breast cancer matter too.
Despite secondary breast cancer being the leading cause of death for women under 60 in the United Kingdom of Great Britain and Northern Ireland, over 40% of British adults have not heard of the disease. There is a lack of awareness. It was quite amazing to know that some of the ladies I met that day with the Minister in Northern Ireland thought that they were cured but found out that they were not, because the full diagnosis had not been done. The hon. Member for Horsham (John Milne) is very knowledgeable about the Lobular Moon Shot Project; he spoke about how more needs to be done, and I want to speak about that as well. It is estimated that some 36% of people cannot name any signs or symptoms of the cancer.
Those figures show that there is much work to be done to ensure that individuals are informed, and that they rapidly access treatment as a result of early diagnosis. We can, however, inform the public only of what we know. Advancements must be made to invest in further research to deepen healthcare professionals’ understanding of the disease and change its prognosis from being a death sentence. Charities such as Breast Cancer Now have already awarded some £300,000 to researchers at Queen’s University Belfast to support an investigation into the inequalities among people living with this disease.
I am very pleased to see the Minister in her place. She encourages us with her interest and compassion for this subject, and I know that she will give us some idea of what has been done at Queen’s University Belfast and the trials that are taking place. We are not that far from finding the cure, and from raising awareness to the level it should be at to save lives and give people hope for the future, long beyond the times that have been allocated. Has the Minister’s Department had an opportunity to talk to Queen’s University Belfast to see what it is doing? Has she had a chance to talk to Mike Nesbitt, the Minister of Health in the Northern Ireland Assembly, to support the investigation into the inequalities among people living with this disease?
The study will consider factors including education, income, disability and mental health—we always say this, because it is the truth: it is not just the ladies who suffer; the families, the children and their in-laws suffer too, because they are all very aware of what is happening—to determine how inequalities influence patients’ access to care, their treatment outcomes and their overall quality of life. Would the Government consider supporting this research at Queen’s University Belfast so that everyone living with the disease across the United Kingdom is given a fair chance to access effective care?
Speaking as my party’s health spokesperson and as a representative from Northern Ireland, I draw attention to the long wait times for cancer referrals in comparison with the rest of the United Kingdom. From July to September 2025, urgent breast cancer referrals in particular saw long delays, with just 6.8% seen within the 14-day target. Over the same time, the Health and Social Care Trust received more than 6,000 referrals for suspected breast cancer, 86% of which were marked as urgent—86%, and no response. With approximately 1,000 living with the disease in Northern Ireland, I must draw attention to the increased risk of women in Northern Ireland experiencing delays in diagnosis and access to treatment.
Cancer treatment should not be a postcode lottery. Advances in treatment mean that more people can now live longer and maintain a good quality of life with secondary breast cancer. While the disease remains incurable, everyone across the United Kingdom of Great Britain and Northern Ireland should have equal access to the treatment and support that they need. I join Members—those who have spoken and those who will speak shortly—in looking to the Minister and simply asking for more: more screening, more funding and more saving of lives.